Static Chart Genome & Company

Equities

End-of-day quote Korea S.E. Other stock markets 03:30:00 27/05/2024 am IST			5-day change	1st Jan Change
9,760 ^KRW	+20.94%		+8.44%	-21.86%

24/01	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

Duration

Period